AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA
The Pharma Data
APRIL 28, 2021
have recently received or are scheduled to receive an immunization (vaccine). You should avoid receiving live vaccines during treatment with SKYRIZI. 2011 Nov;43(7):503-11. SKYRIZI (risankizumab) [Package Insert]. ” have an infection that does not go away or that keeps coming back.
Let's personalize your content